Posted by Michael Wonder on 17 Nov 2021
ICER publishes final evidence report and policy recommendations on mavacamten for hypertrophic cardiomyopathy
16 November 2021 - Concerns about long-term safety influenced majority of independent appraisal committee to vote that evidence is not currently adequate to demonstrate a net health benefit of mavacamten added to background therapy.
The Institute for Clinical and Economic Review today released a Final Evidence Report assessing the comparative clinical effectiveness and value of mavacamten (MyoKardia and Bristol-Myers Squibb) for the treatment of hypertrophic cardiomyopathy.
